Hyperion Therapeutics prices IPO at $10.00, below the range

By Renaissance Capital,

Shutterstock photo

Hyperion Therapeutics, which is focused on the treatment of orphan diseases of the liver relating to the urea cycle, raised $50 million by offering 5 million shares at $10.00, below the range of $11.00 to $13.00. Because Hyperion had planned to offer only 4.2 million shares, there was no change in proceeds raised. Hyperion Therapeutics plans to list on the NASDAQ under the symbol HPTX. Leerink Swann and Cowen & Company acted as lead managers on the deal.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This article appears in: News Headlines IPOs
Referenced Stocks: HPTX

More from Renaissance Capital


Renaissance Capital

Renaissance Capital

Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by BankRate.com